ABT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Abbott Laboratories looks like a good buy right now for a beginner focused on long-term investing with $50,000-$100,000 to deploy. I would rate it as a Buy, but not an aggressive one: the stock is not in a strong momentum breakout, yet the business quality, recent product catalysts, and supportive long-term analyst outlook make it attractive for a patient long-term allocation. Since the investor is unwilling to wait for a perfect entry, buying now is reasonable.
ABT is in a mildly constructive but not strong uptrend. Price closed at 86.08, slightly above the previous close of 85.68, with regular-session gain of 0.72%. MACD histogram is positive at 0.659, which supports upside momentum, but it is contracting, suggesting the move is not accelerating. RSI_6 at 44.688 is neutral, so the stock is neither overbought nor oversold. Moving averages are converging, indicating a consolidation phase rather than a clear trend. Key levels: pivot 86.742, resistance 88.765/90.014, support 84.719/83.47. Overall, the chart suggests a stable base with modest upside potential rather than a powerful breakout.
Recent news is clearly supportive. Abbott received FDA and CE Mark approval for Ultreon 3.0, a first-in-class AI-integrated imaging system for coronary artery imaging. It also launched Libre Duo, a new dual glucose-ketone monitoring system, strengthening its diabetes franchise. The American Cancer Society updated guidelines to endorse Abbott's Cologuard products as preferred noninvasive colorectal cancer screening options, and Abbott is planning a blood-based colorectal cancer test pending FDA approval. These are meaningful event-driven catalysts that improve the long-term growth story across diagnostics, diabetes, and cardiovascular care. Congress trading data is also positive, with more purchases than sales and relatively large trade sizes, suggesting favorable institutional/political attention.
The main negatives are recent analyst downgrades and reduced price targets after a mixed Q1 report. Goldman Sachs removed Abbott from its Conviction List, Daiwa downgraded the stock to Neutral, and several firms cut targets materially. Analysts flagged softer organic growth, especially in MedTech and diabetes, and noted that Q1 did not fully restore confidence in a second-half acceleration. Technically, the stock is not showing a strong momentum surge, and the price trend is only moderate. The stock trend model also points to a possible short-term pullback over the next month.
Financial snapshot data was unavailable due to an error, so a full quarter-by-quarter financial review cannot be completed from the provided data. Based on analyst commentary, the latest quarter appears mixed: topline organic growth was slightly below expectations, adjusted EPS came in a bit ahead, and management kept a long-term growth profile that analysts still view as durable. Several analysts described Abbott as a steady mid-to-high single-digit top-line grower with potential for double-digit EPS growth over time. The latest quarter season referenced is Q1 2026.
Analyst sentiment is still constructive overall, but the trend has weakened. Several firms kept Buy/Outperform/Overweight ratings, yet most reduced price targets after Q1. Recent moves include Daiwa downgrading to Neutral and Goldman Sachs removing Abbott from the Conviction List. Bulls argue the selloff created value, that valuation is near a long-term low, and that growth should re-accelerate into FY26/FY27. Bears focus on softer organic growth and mixed segment performance. Wall Street’s pros still see a durable long-term compounder, but the cons are lowered near-term confidence and slower growth visibility.
